AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29866127 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-delivery refueling service
Number of subjects: 900
Study 29866127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (educational + delivery)
Number of subjects: 900
Study 29866127 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 900
Study 26759975 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD US
Number of subjects: 2759
Study 26759975 — intervention group
Group type: EXPERIMENTAL
Intervention: POC US
Number of subjects: 2759
Study 26759975 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 2759
Study 24793257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 755
Study 24793257 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 755
Study 24793257 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 755
Study 21452177 — intervention group
Group type: EXPERIMENTAL
Intervention: Disengagement strategies
Number of subjects: 271
Study 21452177 — intervention group
Group type: COMPARATOR
Intervention: Engagement strategies
Number of subjects: 271
Study 19838759 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB followed by standardized caloric restriction
Number of subjects: 22
Study 19838759 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction alone (diet)
Number of subjects: 22
Study 18060965 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal sacrocolpopexy with Burch colposuspension
Number of subjects: 305
Study 18060965 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy without Burch colposuspension
Number of subjects: 305
Study 18060965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without Burch)
Number of subjects: 305
Study 15619406 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 42
Study 15619406 — intervention group
Group type: COMPARATOR
Intervention: Metallic stent
Number of subjects: 42
Study 11901445 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 3200 microg of budesonide
Number of subjects: 19
Study 11901445 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus placebo
Number of subjects: 19
Study 9740606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (n=84)
Number of subjects: 175
Study 9740606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril plus hydrochlorothiazide (n=91)
Number of subjects: 175
Study 9740606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril and Lisinopril plus hydrochlorothiazide
Number of subjects: 175
Study 9740606 — intervention group
Group type: EXPERIMENTAL
Intervention: T/P >/=0.5 or <0.5
Number of subjects: 175
Study 9740606 — intervention group
Group type: EXPERIMENTAL
Intervention: T/Ps
Number of subjects: 175
Study 7598069 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (50% of energy as fat)
Number of subjects: 6
Study 7598069 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (25% of energy as fat)
Number of subjects: 6
Study 2112166 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment (Bactroban)
Number of subjects: 60
Study 2112166 — intervention group
Group type: COMPARATOR
Intervention: Oral erythromycin ethylsuccinate
Number of subjects: 60
Study 7044804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (600-1000 mg/day, b.i.d.)
Number of subjects: 110
Study 7044804 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (750-125 mg/day, b.i.d.)
Number of subjects: 110
Study 30705040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept (IVZ) 1.25 mg/0.05 mL administered 1-10 days before PPV
Number of subjects: 206
Study 30705040 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 mL administered 1-10 days before PPV
Number of subjects: 206
Study 29246725 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (Theracurmin® 90 mg twice daily)
Number of subjects: 40
Study 29246725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26707868 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRHa
Number of subjects: 74
Study 26707868 — intervention group
Group type: EXPERIMENTAL
Intervention: OP (FemSeven 100μg/24h patches)
Number of subjects: 74
Study 25123822 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive decision aid
Number of subjects: 131
Study 25123822 — intervention group
Group type: COMPARATOR
Intervention: Brochures
Number of subjects: 131
Study 22715739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dahuang Zhechong Wan combined with adefovir dipivoxil (10 mg of adefovir dipivoxil once a day, 1 Wan each time, combined with Dahuang Zhechong Wan, 3 times a day, 1 Wan each time)
Number of subjects: 94
Study 22715739 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil alone (control group)
Number of subjects: 94
Study 19671263 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1:200000 epinephrine (Part I)
Number of subjects: 106
Study 19671263 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Part I)
Number of subjects: 106
Study 19671263 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1:200000 epinephrine (Part II)
Number of subjects: 106
Study 19671263 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Part II)
Number of subjects: 106
Study 17576400 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with acetate nomegestrol
Number of subjects: 60
Study 17576400 — intervention group
Group type: COMPARATOR
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 60
Study 17211120 — intervention group
Group type: EXPERIMENTAL
Intervention: Education class (2 sessions)
Number of subjects: 40
Study 12439627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 95
Study 12439627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 12439627 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinkers (moderate to heavy use)
Number of subjects: 95
Study 10813372 — intervention group
Group type: EXPERIMENTAL
Intervention: E 047/1 (amiodarone derivative)
Number of subjects: 20
Study 10813372 — intervention group
Group type: EXPERIMENTAL
Intervention: E 047/1 (high-dose bolus regimen)
Number of subjects: 20
Study 8829885 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (Flolan) 2 ng min-1 kg-1
Number of subjects: 14
Study 8829885 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (Flolan) 4 ng min-1 kg-1
Number of subjects: 14
Study 8829885 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (Flolan) 8 ng min-1 kg-1
Number of subjects: 14
Study 8829885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1814875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 94
Study 1814875 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 94
Study 6332895 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate formula supplemented with calcium (92 mg/kg/day), phosphorus (44 mg/kg/day), and vitamin D (500 IU/kg/day)
Number of subjects: 32
Study 6332895 — intervention group
Group type: COMPARATOR
Intervention: Whey-predominant, low osmolality formula
Number of subjects: 32
Study 6332895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 29489408 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (CRT)
Number of subjects: 37
Study 29489408 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 37
Study 28615372 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid (IFA) supplementation
Number of subjects: 1599
Study 28615372 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient (MM) supplementation
Number of subjects: 1599
Study 28615372 — intervention group
Group type: COMPARATOR
Intervention: Folic Acid (FA) alone
Number of subjects: 1599
Study 25740026 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection
Number of subjects: 71
Study 25740026 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 71
Study 23958115 — intervention group
Group type: EXPERIMENTAL
Intervention: MISC biweekly caregiver training
Number of subjects: 60
Study 23958115 — intervention group
Group type: COMPARATOR
Intervention: Health and nutrition curriculum (active control)
Number of subjects: 60
Study 20569667 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (not specifically used by participants but mentioned as a potential prophylaxis for AOM)
Number of subjects: 98
Study 20569667 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to AAP/AAFP guidelines
Number of subjects: 98
Study 20569667 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of complementary and alternative medicine (CAM)
Number of subjects: 98
Study 20569667 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and opinions about xylitol
Number of subjects: 98
Study 17884342 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil-rich diet (10 mL of previously boiled crude palm oil once a day for 2 weeks)
Number of subjects: 34
Study 15726103 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography screening from age 40-41
Number of subjects: 160921
Study 15726103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 160921
Study 14562994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercises (3 times a week for 9 months)
Number of subjects: 21
Study 14562994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no high-impact exercises)
Number of subjects: 21
Study 10476746 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (50 mg/(kg x d))
Number of subjects: 296
Study 10476746 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (120 mg/(kg x d))
Number of subjects: 296
Study 8899132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg/day)
Number of subjects: 600
Study 8899132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg/day)
Number of subjects: 600
Study 8899132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 1676029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40 to 80 mg/day
Number of subjects: 20
Study 1676029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6367863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen added to L-phenylalanine mustard and 5-fluorouracil
Number of subjects: 0
Study 6367863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen added to L-phenylalanine mustard and 5-fluorouracil in patients >= 50 years old
Number of subjects: 0
Study 6367863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen added to L-phenylalanine mustard and 5-fluorouracil in patients <= 49 years old
Number of subjects: 0
Study 6367863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen added to L-phenylalanine mustard and 5-fluorouracil in patients with low estrogen and progesterone levels
Number of subjects: 0
Study 6367863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen added to L-phenylalanine mustard and 5-fluorouracil in patients with high estrogen and progesterone levels
Number of subjects: 0
Study 31819319 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion (1.5 pmol/kg/min)
Number of subjects: 14
Study 31819319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mL of 0.9% saline)
Number of subjects: 14
Study 29039254 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine infusion
Number of subjects: 55
Study 24632987 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina pectoris class >2
Number of subjects: 535
Study 24632987 — intervention group
Group type: COMPARATOR
Intervention: Angina pectoris class ≤2
Number of subjects: 535
Study 23817151 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable antipsychotics
Number of subjects: 113
Study 21482191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg
Number of subjects: 1176
Study 21482191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg
Number of subjects: 1176
Study 21482191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1176
Study 19185467 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 to 20 mg/day)
Number of subjects: 777
Study 19185467 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 777
Study 19185467 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 to 40 mg/day)
Number of subjects: 777
Study 17915406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy
Number of subjects: 0
Study 17915406 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 0
Study 17915406 — intervention group
Group type: COMPARATOR
Intervention: Oral regimen
Number of subjects: 0
Study 17915406 — intervention group
Group type: COMPARATOR
Intervention: Transdermal regimen
Number of subjects: 0
Study 15043514 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel (100 mL twice daily for 4 weeks)
Number of subjects: 44
Study 15043514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered QRS duration (FQRSD)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Root mean square amplitude of the last 40 ms (RMS40)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency low amplitude signals less than 40 microV (HFLAS40)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Total QRS duration (TQRSD)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Power spectral density of the last 40 ms
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Late potential duration of time domain analogous analyses
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral score variables (low slice correlation ratio)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral score variables (spectral entropy)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral score variables (interslice correlation mean)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral score variables (interslice correlation SD)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean peaks per slice (replacing interslice correlation SD)
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reproducibility of time domain and time domain analogous variables
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term reproducibility
Number of subjects: 121
Study 10819404 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility in women and younger people
Number of subjects: 121
Study 9110921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beta-hCG (2500-25000 IU/day)
Number of subjects: 8
Study 9110921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose beta-hCG (25000-100000 IU/day)
Number of subjects: 8
Study 9110921 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-hCG therapy
Number of subjects: 8
Study 8478852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment for osteoarthritis; 18 half-hour periods of exposure over about 1 month.
Number of subjects: 27
Study 8478852 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 27
Study 2823863 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded bran product (period B)
Number of subjects: 7
Study 2823863 — intervention group
Group type: COMPARATOR
Intervention: Bran-gluten-starch mixture (period A)
Number of subjects: 7
Study 30678686 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2000 mg/day
Number of subjects: 181
Study 30678686 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with combination nutraceutical treatment (CT) 2000 mg/day
Number of subjects: 181
Study 30678686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 27321772 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD protocol (mixed drops: 4:3:3 ratio of 1% tropicamide, 10% phenylephrine, 0.1% diclofenac)
Number of subjects: 30
Study 27321772 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (1% tropicamide, 10% phenylephrine, 0.1% diclofenac in separate bottles)
Number of subjects: 30
Study 27321772 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD protocol
Number of subjects: 30
Study 27321772 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 30
Study 25695686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatome technique with soft tissue removal
Number of subjects: 47
Study 25695686 — intervention group
Group type: COMPARATOR
Intervention: Linear incision with no soft tissue reduction
Number of subjects: 47
Study 23432848 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk
Number of subjects: 197
Study 23432848 — intervention group
Group type: COMPARATOR
Intervention: Control dairy product
Number of subjects: 197
Study 21157394 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational weight training (RWT) participants
Number of subjects: 88
Study 21157394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RWT participation)
Number of subjects: 88
Study 21157394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 19414635 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human a-galactosidase A treatment for 5 months
Number of subjects: 58
Study 19414635 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 5 months
Number of subjects: 58
Study 19414635 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human a-galactosidase A treatment continued in open-label trial
Number of subjects: 58
Study 17563216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 103
Study 17563216 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 103
Study 15386481 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 200 mg
Number of subjects: 23
Study 15386481 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 150 mg
Number of subjects: 23
Study 15386481 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan (various doses 5-200 mg)
Number of subjects: 23
Study 11311845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Education Program (DEPB)
Number of subjects: 2055
Study 11311845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 2055
Study 10092916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment: Daily 100-minute treatments with 100% oxygen at 2.8 atmospheres absolute for three days (or six days for clinically abnormal patients).
Number of subjects: 0
Study 10092916 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen (NBO) treatment: Daily 100-minute treatments with 100% oxygen at 1.0 atmosphere absolute for three days (or six days for clinically abnormal patients).
Number of subjects: 0
Study 7759785 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone i.m. (50 mg/day)
Number of subjects: 176
Study 7759785 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (hCG) (2000 IU every three days)
Number of subjects: 176
Study 7759785 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal cream (100 mg/day)
Number of subjects: 176
Study 7759785 — intervention group
Group type: COMPARATOR
Intervention: Nothing (controls)
Number of subjects: 176
Study 2310915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously injected contrast media (both peripheral and central injection)
Number of subjects: 0
Study 2310915 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium with varying osmolality
Number of subjects: 0
Study 44124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.0635 to 0.5 mg/70 kg
Number of subjects: 21
Study 44124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg/70 kg
Number of subjects: 21
Study 44124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 2‐4 mg/70 kg
Number of subjects: 21
Study 31860604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients fulfilling all criteria for eCPR
Number of subjects: 92
Study 31860604 — intervention group
Group type: COMPARATOR
Intervention: Patients not fulfilling all criteria for eCPR
Number of subjects: 92
Study 31154805 — intervention group
Group type: EXPERIMENTAL
Intervention: Late winter (n=98)
Number of subjects: 150
Study 31154805 — intervention group
Group type: EXPERIMENTAL
Intervention: Late summer (n=52)
Number of subjects: 150
Study 31154805 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 24-48 months
Number of subjects: 150
Study 28750015 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected vaginal dry swabs (s-DRY)
Number of subjects: 150
Study 28750015 — intervention group
Group type: COMPARATOR
Intervention: Physician-collected cervical sampling (dr-WET)
Number of subjects: 150
Study 28750015 — intervention group
Group type: COMPARATOR
Intervention: Cobas HPV test
Number of subjects: 150
Study 28750015 — intervention group
Group type: COMPARATOR
Intervention: Comparison of s-DRY and dr-WET
Number of subjects: 150
Study 26639093 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 205
Study 26639093 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 205
Study 23298271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine and cisplatin (Navelbine and platinum [NP]) with rh-endostatin
Number of subjects: 74